<DOC>
	<DOCNO>NCT00038233</DOCNO>
	<brief_summary>The objective protocol assess therapeutic activity thalidomide previously untreated patient asymptomatic multiple myeloma .</brief_summary>
	<brief_title>Thalidomide Multiple Myeloma</brief_title>
	<detailed_description>This study attempt examine potential efficacy thalidomide treatment patient previously untreated multiple myeloma . The trial focus patient asymptomatic indolent disease require immediate chemotherapy . We intend treat asymptomatic patient initial dose 200 mg evening , increase maximum 800 mg. Thalidomide supply 50 mg capsule take mouth . The initial dose 200 mg bedtime daily 14 day ( day 1-14 ) , follow increase 400 mg daily 14 day ( day 15-28 ) , 600 mg daily 14 day ( day 29-42 ) , maximum 800 mg ( day 43-completion ) daily provide side effect . Patients experience significant toxicity ( grade 2 ) time therapy receive low dose treatment interrupt least 2 day . Once maximum tolerate dose reach free side effect , dose continued total 3 month institution therapy definition response resistance . Only patient receive least 200 mg/d least 2 month consider evaluable response . For patient remission , treatment continue maximum dose free side effect relapse . Selected patient &lt; 55 year age achieve remission may eligible stem cell transplant ( SCT ) case thalidomide discontinue prior SCT . Patients must willing return evaluation every 4 week since thalidomide may prescribe 28 day interval .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Previously untreated patient multiple myeloma without serious imminent complication ( e.g . impend pathologic fracture , hypercalcemia , renal insufficiency ) . All asymptomatic patient low intermediate tumor mass qualify . Patients high tumor mass , symptomatic impending fracture , hypercalcemia ( correct calcium &gt; 11.5 mg % ) , anemia ( Hgb &lt; 8.5 gm/dl ) , renal failure ( creatinine &gt; 2.0 mg/dl ) , high serum lactate dehydrogenase ( &gt; 300 U/L ) plasma cell leukemia ( &gt; 1000/ul ) ineligible . Overt infection unexplained fever resolve treatment . Adequate liver function ( include SGPT , bilirubin LDH ) require . Patients must Zubrod performance 1 less . Patients must provide write informed consent indicate aware investigational nature study . Life expectancy exceed 1 year . Patients idiopathic monoclonal gammopathy nonsecretory multiple myeloma ineligible . Patients whose prior therapy local radiotherapy , alphaIFN , ATRA eligible . Patients expose prior highdose glucocorticoid alkylating agent eligible .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>myeloma</keyword>
</DOC>